Vertex, Glaxo's Lexiva provided comparable efficacy to Kaletra in study

By Elaine Rigoli

Tampa, Fla., Aug. 17 - Vertex Pharmaceuticals, Inc. and GlaxoSmithKline, Inc. said a clinical study shows that HIV regimens using Lexiva (Telzir) tablets plus ritonavir and Kaletra (lopinavir/ritonavir) capsules both given twice daily had comparable efficacy and tolerability in adults who had no previous exposure to HIV medicines.

Lexiva is indicated for the treatment of HIV infection in adults in combination with other antiretroviral medications.

"Protease inhibitors continue to be a key component of antiretroviral therapy and this new information reinforces the efficacy and safety of Lexiva/r for treatment-naive patients with HIV," said Joseph Eron Jr., professor of medicine at the University of North Carolina at Chapel Hill, in a news release.

GlaxoSmithKline is a London-based pharmaceutical company.

Vertex is a biotechnology company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.